Barriers of Treating EGFR-Mutant NSCLC With Adjuvant Osimertinib
Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.
Nathan Pennell, MD, PhD, a medical oncologist at the Cleveland Clinic, discusses the cost-effectiveness of adjuvant osimertinib (Tagrisso) in resected EGFR-mutant non-small cell lung cancer (NSCLC).
According to Pennell, at a 5% improvement in survival, osimertinib has a cost effectiveness ratio of $317,000, much higher than the commonly drug cost of $195,000 in the United States. This means, at the current cost, adjuvant osimertinib does not appear to be cost effective in this patient population.
However, the hope is that osimertinib turns out to be much more effective than previously reported, according to Pennell. If the effectiveness rate is between 25% to 30%, the agent would prove to be cost effective at the current standard. Additionally, if osimertinib was half the price, the drug would be cost-effective at 5%.
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
